The interaction and binding of ligand-receptor HA-CD44 regulate the downstream cytoskeleton pathways involve in cell survival or cell death. Thus, targeting HA, CD44 (variant and standard) isoform, and HA-CD44 binding consider as an attractive and …

CD44 and receptor for HA-mediated motility (RHAMM) are the two main HA-receptors whose biological functions in human and murine inflammations and tumor cells have been investigated comprehensively.

The CD44 structure of normal cells is distinct from that of cancer cells because pathological conditions promote alternate splicing and post translational modifications to produce diversified CD44 molecules with enhanced HA binding that leads to increased tumorigenicity [30–36].

2018年5月10日 · Here, we review current data on the structural and functional properties of CD44, the known roles for CD44 in tumorigencity, the regulation of CD44 expression, and the potential for targeting CD44 for cancer therapy.

In this study, we have established quantitative relationships between CD44 expression in differently polarized macrophages (M0, M1, and M2-polarized THP-1 human macrophages) and the uptake of hyaluronic acid (HA)-based materials, which are …

2020年10月6日 · Our results revealed that an ER-CD44-HA signaling circuit that mediates robust compensatory activation of the Src-ERK signaling cascade may contribute to the development of acquired resistance to...

2017年5月1日 · HA is used by several investigators as a vehicle to transport anticancer drugs for at least three reasons. First, HA binds CD44 variants. Second, HA-drug conjugate is concentrated on the cell surface and internalized. Third, toxicity due to …

2023年10月31日 · Hyaluronic acid (HA) receptor CD44 is widely used for identifying cancer stem cells and its activation promotes stemness. Recent evidence shows that overexpression of CD44 is associated with poor prognosis in most human cancers and mediates therapy resistance.

2021年9月3日 · There is ample evidence showing that both CD44 and HA are abundantly expressed at sites of tumor attachment and binding of HA to the extracellular domain of CD44 stimulates several tumor cell-specific behaviors, suggesting that CD44 activation may play an indispensable role in tumor progression.

Understanding how CD44 and HA regulate inflammation in atherogenesis is key in determining the utility of the CD44-HA axis as a therapeutic target to halt disease and potentially promote disease regression.